[go: up one dir, main page]

PE20050948A1 - CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV - Google Patents

CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Info

Publication number
PE20050948A1
PE20050948A1 PE2004000875A PE2004000875A PE20050948A1 PE 20050948 A1 PE20050948 A1 PE 20050948A1 PE 2004000875 A PE2004000875 A PE 2004000875A PE 2004000875 A PE2004000875 A PE 2004000875A PE 20050948 A1 PE20050948 A1 PE 20050948A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
carbamoil
inhibitors
trans
amino
Prior art date
Application number
PE2004000875A
Other languages
Spanish (es)
Inventor
Kota Asahina
Yuki Kitao
Satoru Kobayashi
Kenichi Matsui
Masaki Yamashita
Hisashi Shinkai
Toshio Taniguchi
Kazuhiro Tsutsumi
Tomohiro Oda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34317220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20050948A1 publication Critical patent/PE20050948A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CARBAMOIL-AMINA DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOALQUILO (C3-C12) OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), OPCIONALMENTE SUSTITUIDOS; R3 ES CICLOALQUILO(C3-C12) OPCIONALMENTE SUSTITUIDO; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), HETEROCICLO SATURADO DE 3 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 2-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METILACARBAMOIL)METIL]CICLOHEXILMETOXIMETIL}BENZOICO, ACIDO 3-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METIL-CARBAMOIL)METIL]CICLOHEXILMETOXIMETIL-5-DIMETILAMINOBENZOICO, (2-METANOSULFONIL)FENILAMIDA DE ACIDO TRANS 4-[(S)-AMINO-(N-CICLOBUTIL-N-METILCARBAMOIL)METIL]CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL PEPTIDASA DPP-IV, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE LA DIABETES TIPO II, OBESIDAD O SIMILARESREFERS TO COMPOUNDS DERIVED FROM CARBAMOIL-AMINE OF FORMULA (I), WHERE R1 IS H, ALKYL (C1-C6), OPTIONALLY SUBSTITUTED CYCLOALKYL (C3-C12), AMONG OTHERS; R2 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), OPTIONALLY SUBSTITUTED; R3 IS CYCLOALKYL (C3-C12) OPTIONALLY SUBSTITUTED; R4 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), SATURATED HETEROCYCLE OF 3 TO 7 MEMBERS, OPTIONALLY REPLACED. PREFERRED COMPOUNDS ARE: 2- {TRANS-4 - [(S) -AMINO- (N-CYCLOBUTYL-N-METHYLACARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL} BENZOIC ACID, 3- {TRANS-4 - [(S) -AMINO- ( N-CYCLOBUTYL-N-METHYL-CARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL-5-DIMETHYLAMINOBENZOIC, (2-METHANOSULFONYL) TRANS 4 ACID PHENYLAMIDE - [(S) -AMINO- (N-CYCLOBUTILBUTYL-N-METHYLOCAR) HEXYLBUTYL-N-METHYLOCARYL OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF THE DIPEPTIDIL PEPTIDASE DPP-IV ENZYME, SO THEY ARE USEFUL FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, OR SIMILAR

PE2004000875A 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV PE20050948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003317407 2003-09-09
JP2003395879 2003-11-26
JP2004114685 2004-04-08

Publications (1)

Publication Number Publication Date
PE20050948A1 true PE20050948A1 (en) 2005-12-16

Family

ID=34317220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000875A PE20050948A1 (en) 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Country Status (4)

Country Link
AR (1) AR046330A1 (en)
PE (1) PE20050948A1 (en)
TW (1) TW200530157A (en)
WO (1) WO2005025554A2 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374181T1 (en) 2001-06-27 2007-10-15 Smithkline Beecham Corp FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
ES2295816T3 (en) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. ARILO AND HETEROARILO 1,2,3-TRISUSTITUTED DERIVATIVES AS METABOLISM MODULATORS, AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME, SUCH AS DIABETES AND HYPERGLUCEMIA.
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
JP5774264B2 (en) * 2005-04-27 2015-09-09 アリーナ ファーマシューティカルズ， インコーポレイテッド Combination therapy for the treatment of obesity and diabetes, and conditions associated therewith, and for the treatment of conditions that are alleviated by increasing blood GLP-1 levels
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
KR20090004950A (en) 2006-04-12 2009-01-12 프로비오드룩 아게 Enzyme inhibitor
EP2054051B1 (en) * 2006-08-16 2013-02-27 Amderma Pharmaceuticals, Llc Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
JP5605844B2 (en) 2008-10-17 2014-10-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
CN102695546B (en) 2009-09-11 2014-09-10 前体生物药物股份公司 Heterocylcic derivatives as inhibitors of glutaminyl cyclase
AU2010303270A1 (en) * 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP2013523819A (en) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド GPR119 receptor modulators and treatment of disorders related thereto
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP5912112B2 (en) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Amide insulin prodrug
KR20130043207A (en) 2010-07-22 2013-04-29 자프겐 인크. Tricyclic compounds and methods of making and using same
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR20140053013A (en) 2011-05-06 2014-05-07 자프겐 인크. Tricyclic sulfonamide compounds and methods of making and using same
PH12013502261A1 (en) 2011-05-06 2022-10-26 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112014017780A8 (en) 2012-01-18 2017-07-11 Zafgen Inc TRICYCLIC SULPHONE COMPOUNDS AND METHODS FOR MAKING AND USING THEM
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN104870433A (en) 2012-11-05 2015-08-26 扎夫根股份有限公司 Tricyclic compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
JP6169716B2 (en) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド How to treat liver disease
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2964276A1 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
EP3262028B1 (en) 2014-12-17 2021-10-27 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
PL3242666T3 (en) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
AU2017246706B2 (en) * 2016-04-04 2020-09-17 Research Triangle Institute Neuropeptide s receptor (NPSR) agonists
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR102859841B1 (en) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. Treatment of conditions associated with the S1P1 receptor
US10683267B1 (en) * 2019-11-21 2020-06-16 King Abdulaziz University Antidiabetic compounds
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
WO2025131062A1 (en) * 2023-12-21 2025-06-26 江苏恒瑞医药股份有限公司 Olefin compound, preparation method therefor and use thereof in medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
SE9701245D0 (en) * 1997-04-04 1997-04-04 Bjoern Classon antivirals
CO5150173A1 (en) * 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
EP1434769A2 (en) * 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7727964B2 (en) * 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes

Also Published As

Publication number Publication date
AR046330A1 (en) 2005-12-07
WO2005025554A2 (en) 2005-03-24
TW200530157A (en) 2005-09-16
WO2005025554A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
ECSP088765A (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20060921A1 (en) PROCEDURE TO PREPARE CHIRAL 8- (3-AMINO-PIPERIDIN-1-IL) -XANTHINES
PE20081836A1 (en) PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE
PE20070367A1 (en) SPIROPIPERIDINE COMPOUNDS AS INHIBITORS OF THE BETA SECRETASE ENZYME
PE20050121A1 (en) TIENYL-HYDROXAMIC ACIDS, SUBSTITUTED REFERRED TO THE ENZYMATIC ACTIVITY OF HISTONE DESACETILASE
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
NI201100081A (en) AMINOTETRAHYDROPYRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE - IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
PE20050012A1 (en) BENZOPYRANE COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITORS
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
ECSP088891A (en) BICYCLIC DERIVATIVES AS CETP INHIBITORS
AR053415A1 (en) DIPEPTIDIL PEPTIDASA IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF COMPOUNDS AND COMPOSITION
PE20091834A1 (en) 2-IMINO-3-METHYLPYRROLOOPYRIMIDINONE THIOPHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS AND COMPOSITIONS CONTAINING THEM
PE20081504A1 (en) REPLACED BICYCLOCARBOXIAMIDE COMPOUNDS
PE20071326A1 (en) VIRAL POLYMERASE INHIBITORS
PE20141726A1 (en) HETEROCYCLYLAMINES AS 3K PI INHIBITORS
PE20060316A1 (en) PROLIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS
PE20090880A1 (en) HETEROCYCLIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
PE20040898A1 (en) NEW COMPOUNDS DERIVED FROM PYRIMIDINE
AR073348A1 (en) CYCLE INHIBITORS OF 11 BETA-HYDROXIESTEROID DEHYDROGENASE 1
PE20120620A1 (en) DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES
PE20050864A1 (en) HETEROCICLYLAMINE COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1
PE20130311A1 (en) COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING TRACK

Legal Events

Date Code Title Description
FA Abandonment or withdrawal